These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

943 related items for PubMed ID: 22176652

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE, Lemieux V, Noad J, Moore JI, Dewpura T, Raymond A, Chrétien M, Figeys D, Mayne J.
    FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
    [Abstract] [Full Text] [Related]

  • 3. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D, Pöss J, Böhm M, Laufs U.
    J Am Coll Cardiol; 2013 Oct 15; 62(16):1401-8. PubMed ID: 23973703
    [Abstract] [Full Text] [Related]

  • 4. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
    Schmidt RJ, Beyer TP, Bensch WR, Qian YW, Lin A, Kowala M, Alborn WE, Konrad RJ, Cao G.
    Biochem Biophys Res Commun; 2008 Jun 13; 370(4):634-40. PubMed ID: 18406350
    [Abstract] [Full Text] [Related]

  • 5. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J, Bogsrud MP, Tveten K, Strøm TB, Holven K, Berge KE, Leren TP.
    Transl Res; 2012 Aug 13; 160(2):125-30. PubMed ID: 22683370
    [Abstract] [Full Text] [Related]

  • 6. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
    Tai MH, Chen PK, Chen PY, Wu MJ, Ho CT, Yen JH.
    Mol Nutr Food Res; 2014 Nov 13; 58(11):2133-45. PubMed ID: 25164566
    [Abstract] [Full Text] [Related]

  • 7. Local effects of human PCSK9 on the atherosclerotic lesion.
    Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, DeVay RM, Hong L, Fan D, Predazzi IM, Rashid S, Linton MF, Fazio S.
    J Pathol; 2016 Jan 13; 238(1):52-62. PubMed ID: 26333678
    [Abstract] [Full Text] [Related]

  • 8. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M, Terao Y, Ayaori M, Uto-Kondo H, Iizuka M, Yogo M, Hagisawa K, Takiguchi S, Yakushiji E, Nakaya K, Ogura M, Komatsu T, Ikewaki K.
    Arterioscler Thromb Vasc Biol; 2014 Jun 13; 34(6):1171-8. PubMed ID: 24675665
    [Abstract] [Full Text] [Related]

  • 9. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
    Wang Y, Ye J, Li J, Chen C, Huang J, Liu P, Huang H.
    Cardiovasc Diabetol; 2016 Feb 01; 15():19. PubMed ID: 26833058
    [Abstract] [Full Text] [Related]

  • 10. Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly.
    Holla ØL, Cameron J, Berge KE, Ranheim T, Leren TP.
    BMC Cell Biol; 2007 Mar 01; 8():9. PubMed ID: 17328821
    [Abstract] [Full Text] [Related]

  • 11. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
    Maxwell KN, Fisher EA, Breslow JL.
    Proc Natl Acad Sci U S A; 2005 Feb 08; 102(6):2069-74. PubMed ID: 15677715
    [Abstract] [Full Text] [Related]

  • 12. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
    Ason B, van der Hoorn JW, Chan J, Lee E, Pieterman EJ, Nguyen KK, Di M, Shetterly S, Tang J, Yeh WC, Schwarz M, Jukema JW, Scott R, Wasserman SM, Princen HM, Jackson S.
    J Lipid Res; 2014 Nov 08; 55(11):2370-9. PubMed ID: 25258384
    [Abstract] [Full Text] [Related]

  • 13. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.
    Le QT, Blanchet M, Seidah NG, Labonté P.
    J Biol Chem; 2015 Sep 18; 290(38):23385-400. PubMed ID: 26195630
    [Abstract] [Full Text] [Related]

  • 14. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
    Duan Y, Chen Y, Hu W, Li X, Yang X, Zhou X, Yin Z, Kong D, Yao Z, Hajjar DP, Liu L, Liu Q, Han J.
    J Biol Chem; 2012 Jul 06; 287(28):23667-77. PubMed ID: 22593575
    [Abstract] [Full Text] [Related]

  • 15. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
    Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S.
    Circulation; 2014 Jul 29; 130(5):431-41. PubMed ID: 25070550
    [Abstract] [Full Text] [Related]

  • 16. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A.
    Hepatology; 2008 Aug 29; 48(2):646-54. PubMed ID: 18666258
    [Abstract] [Full Text] [Related]

  • 17. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
    Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S.
    Circulation; 2013 Jun 18; 127(24):2403-13. PubMed ID: 23690465
    [Abstract] [Full Text] [Related]

  • 18. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
    Maxwell KN, Breslow JL.
    Proc Natl Acad Sci U S A; 2004 May 04; 101(18):7100-5. PubMed ID: 15118091
    [Abstract] [Full Text] [Related]

  • 19. Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport.
    Shen L, Peng HC, Nees SN, Zhao SP, Xu DY.
    FEBS Lett; 2013 May 02; 587(9):1271-4. PubMed ID: 23499248
    [Abstract] [Full Text] [Related]

  • 20. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms.
    Katsuki S, K Jha P, Lupieri A, Nakano T, Passos LSA, Rogers MA, Becker-Greene D, Le TD, Decano JL, Ho Lee L, Guimaraes GC, Abdelhamid I, Halu A, Muscoloni A, V Cannistraci C, Higashi H, Zhang H, Vromman A, Libby P, Keith Ozaki C, Sharma A, Singh SA, Aikawa E, Aikawa M.
    Circ Res; 2022 Nov 11; 131(11):873-889. PubMed ID: 36263780
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.